Highlight
– In ADAPT AF‑DES (N=960), NOAC monotherapy was noninferior to NOAC plus clopidogrel for net adverse clinical events at 12 months and demonstrated superiority (absolute difference −7.6 percentage points; HR 0.54).
– Major or clinically relevant nonmajor bleeding was markedly lower with NOAC alone (5.2% vs 13.2%; HR 0.38).
